KNIGHT THERAPEUTICS INC.

Management's Discussion and Analysis

For the quarter ended September 30, 2018

The following is Management's Discussion and Analysis of the financial condition and operating results of Knight Therapeutics Inc. ("Knight" or the "Company") for the three and nine months ended September 30, 2018. This document should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto for the three and nine months ended September 30, 2018 and the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations in our annual report for the year ended December 31, 2017. Knight's unaudited interim condensed consolidated financial statements as at and for the three and nine months ended September 30, 2018 have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting". All amounts herein are expressed in thousands of Canadian dollars (unless otherwise indicated) except for share and per share amounts. All other currencies are in thousands.

This discussion and analysis was prepared by management from information available as at November 7, 2018. Further information about Knight Therapeutics Inc., including the Annual Information Form, is available online on SEDAR at www.sedar.com.

Cautionary note regarding forward-looking statements

This Management's Discussion and Analysis may contain certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Factors and risks which could cause actual results to differ materially from current expectations are discussed in the Company's Annual Report and in the Company's Annual Information Form for the year ended December 31, 2017 found on SEDAR at www.sedar.com. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

TABLE OF CONTENTS

(In thousands of Canadian dollars, except for share and per share amounts)

GLOSSARY OF ABBREVIATIONS

Abbreviation	Calendar
YTD-18	Nine-month period ended September 30, 2018
YTD-17	Nine-month period ended September 30, 2017
Q3-18	Third quarter of 2018
Q2-18	Second quarter of 2018
Q1-18	First quarter of 2018
Q4-17	Fourth quarter of 2017
Q3-17	Third quarter of 2017
Q2-17	Second quarter of 2017
Q1-17	First quarter of 2017
Q4-16	Fourth quarter of 2016

Abbreviation	Company
60P	60^{o} Pharmaceuticals LLC
Advaxis	Advaxis Pharmaceuticals Inc.
Akorn	Akorn Inc.
Alimera	Alimera Sciences Inc.
Antibe	Antibe Therapeutics Inc.
AstraZeneca	AstraZeneca AB
Braeburn	Braeburn Pharmaceuticals Inc.
Crescita	Crescita Therapeutics Inc.
Ember	Ember Therapeutics Inc.
Forbion	Forbion Capital Fund III CV
Jaguar	Jaguar Health Inc.
Knight or the Company	Knight Therapeutics Inc.
Lundbeck	H. Lundbeck A/S
Medimetriks	Medimetriks Pharmaceuticals Inc.
Medison	Medison Biotech (1995) Ltd.
NEMO II	New Emerging Medical Opportunities Fund II Ltd.
NEMO III	New Emerging Medical Opportunities Fund III Ltd.
NeurAxon	NeurAxon Pharma Inc.
PBB	Pro Bono Bio PLC
Pediapharm	Pediapharm Inc.
Prexton	Prexton Therapeutics SA
Profound	Profound Medical Inc.
Replimune	Replimune Group Inc
Sectoral	Sectoral Asset Management Inc.
SIFI	Società Industria Farmaceutica Italiana S.p.A.
Synergy	Synergy CHC Corp.
TXMD	TherapeuticsMD, Inc.

Abbreviation	Financial
AOCI	Accumulated other comprehensive income
C$ or $	Canadian Dollar
DC&P	Disclosure Controls and Procedures
EPS	Earnings per share to common shareholders
EUR	Euro
FMV	Fair market value
ICFR	Internal control over financial reporting
IFRS	International Financial Reporting Standards
ILS	New Israeli Shekels
Interim Financial Statements	Unaudited interim condensed consolidated financial statements
OCI	Other comprehensive income
US$	U.S. Dollar

Abbreviation	Territory
CAN	Canada
CAR	Select countries in the Caribbean
ISR	Israel
LATAM	Latin America
QUE	Quebec
ROM	Romania
RUS	Russia
UAE	United Arab Emirates
U.S.	United States of America
ZAF	Sub-Saharan Africa

Abbreviation	Other
AIDS	Acquired immune deficiency syndrome
ART	Antiretroviral Therapy
HIV	Human immunodeficiency virus infection
IBS-C	Irritable Bowel Syndrome with Constipation
IPO	Initial Public Offering
IQVIA	IQVIA Incorporated, a leading pharmaceutical market research organization
NDS	New Drug Submission
OIC	Opioid-induced constipation
PMPRB	Patented Medicine Prices Review Board
PRV	Priority Review Voucher

OVERVIEW

Section 1 – About Knight Therapeutics Inc.

Knight Therapeutics Inc. is a specialty pharmaceutical company, headquartered in Montreal, Canada, and listed on Toronto Stock Exchange under the ticker symbol "GUD". Activities performed by the Company are as follows:

- Principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets.
- Finances other life sciences companies with the goal of strengthening relationships in the life science industry and securing product distribution rights for Canada and select international markets.
- Invests in life sciences venture capital funds whereby the Company receives preferential access to innovative healthcare products for Canada and select international markets.
- Develops innovative pharmaceutical products including those to treat neglected tropical and rare pediatric diseases.

Section 2 – Q3-18 Highlights

Financial Results

- Revenues were $3,220, an increase of $1,360 or 73% over prior year.
- Net gain on financial assets measured at fair value through profit or loss of $10,924 due to disposals and changes in fair values of financial assets.
- Net income was $12,930, an increase of $9,337 or 260% over prior year.
- Cash outflow from operations at $19,916 compared to cash inflows of $10,736 in prior year.

Corporate Developments

- Received notice of reassessment from CRA of $23,340 related to the sale of the PRV in 2014.
- Accepted the resignation of Dr. Sarit Assouline and appointed Nancy Harrison on the Board of Directors.

Products

- Entered into a licensing agreement with TXMD to commercialize TX-004HR and TX-001HR in Canada and Israel.
- Entered into a distribution, license and supply Agreement with Jaguar to commercialize Mytesi® in Canada and Israel.
- Entered into an out-licensing agreement with Pharma Consulting Group S.A. for the commercial rights of Impavido® in Colombia, Peru, Ecuador and Paraguay.

Strategic Lending

- Received $3,188 representing full loan repayment and early payment fee from Profound.

Strategic Investments

- Invested $26,028 [USD$20,000] in common shares of TXMD at a price of US$5.10 per share.
- Received distributions of $328 from strategic fund investments.

Subsequent Events

- Invested $1,161 [USD$900] in common shares of Jaguar at a price of US$0.60 per share.
- Launched Probuphine™, for the management of opioid dependence, in Canada.

(In thousands of Canadian dollars, except for share and per share amounts)

FINANCIAL RESULTS

Section 3 – Results of Operations

			Change				Change	
	Q3-18	Q3-17	**$[1]**	**%[2]**	**YTD-18**	YTD-17	**$[1]**	**%[2]**
Revenues	**3,220**	1,860	1,360	73%	**8,612**	6,090	2,522	41%
Cost of goods sold	**609**	337	(272)	81%	**1,781**	1,097	(684)	62%
Gross margin	**2,611**	1,523	1,088	71%	**6,831**	4,993	1,838	37%
Gross margin (%)	***81%***	*82%*	*1%*	*1%*	***79%***	*82%*	*3%*	*3%*
Expenses								
Selling and marketing	**1,000**	834	(166)	20%	**2,681**	2,247	(434)	19%
General and administrative	**1,833**	2,147	314	15%	**5,865**	6,944	1,079	16%
Research and development	**438**	586	148	25%	**1,499**	1,869	370	20%
	(660)	(2,044)	1,384	68%	**(3,214)**	(6,067)	2,853	47%
Depreciation of property and equipment	**28**	—	(28)	100%	**63**	—	(63)	100%
Amortization of intangible assets	**481**	539	58	11%	**1,367**	1,185	(182)	15%
Interest income	**(4,956)**	(6,959)	(2,003)	29%	**(14,990)**	(18,517)	(3,527)	19%
Other income	**(385)**	(871)	(486)	56%	**(1,773)**	(1,513)	260	17%
Net gain on financial assets	**—**	(1,317)	(1,317)	N/A	**—**	(3,636)	(3,636)	N/A
Net gain on financial assets measured at fair value through profit or loss	**(10,924)**	—	10,924	100%	**(14,349)**	—	14,349	100%
Share of net income of associate	**(89)**	(98)	(9)	9%	**(441)**	(513)	(72)	14%
Foreign exchange loss (gain)	**1,117**	2,695	1,578	59%	**(1,431)**	4,244	5,675	N/A
Income before income taxes	**14,068**	3,967	10,101	255%	**28,340**	12,683	15,657	123%
Income tax expense (recovery)								
Current	**1,891**	490	(1,401)	286%	**3,443**	1,598	(1,845)	115%
Deferred	**(753)**	(116)	637	549%	**1,039**	986	(53)	5%
Net income for the period	**12,930**	3,593	9,337	260%	**23,858**	10,099	13,759	136%
Attributable to shareholders of the Company								
Basic EPS	**0.091**	0.025	0.066	264%	**0.167**	0.071	0.096	135%
Diluted EPS	**0.090**	0.025	0.065	260%	**0.167**	0.070	0.097	139%

[1] *A positive variance represents a positive impact to net income and a negative variance represents a negative impact to net income*
[2] *Percentage change is presented in absolute values*

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-18 vs Q3-17	YTD-18 vs YTD-17
Revenues	• Increase in revenues mainly attributable to timing of sales of Impavido® and growth in Movantik® sales.	
Gross margin	• Increase in gross margin ($) attributable to increase in revenues. • Decrease in gross margin (%) attributable to change in product mix.	
Selling and marketing	• Increase due to commercial activities including sales force promotion of Movantik® and preparation of the launch of new products.	
General and administrative	• Decrease mainly related to lower stock-based compensation expense.	
Research and development expenses	• No significant variance.	
Depreciation and amortization	• No significant variance.	
Interest income	• Primarily from interest earned on loans, cash and cash equivalents, marketable securities and accretion on loans receivable. ***Interest Income*** • Interest income (excluding accretion) for Q3-18 was $4,956, a decrease of 14% or $806 compared to prior year due to a lower average loan balance offset by an increase in the average cash, cash equivalents and marketable securities balances and an increase in interest rates. ***Interest Accretion*** • No significant interest accretion in Q3-18 compared to $1,197 in prior year due to the adoption of IFRS 9.	***Interest Income*** • Interest income (excluding accretion) for YTD-18 was $14,990, a decrease of 1% or $146 compared to prior year due to a lower average loan balance offset by an increase in the average cash, cash equivalents and marketable securities balances and an increase in interest rates ***Interest Accretion*** • No significant interest accretion in YTD-18 compared to $3,381 in prior year due to the adoption of IFRS 9.
Other income[1]	• Amount in Q3-18 primarily driven by the repayment fee of the Profound loan.	• Amount in YTD-18 driven by the early repayment fees on the Medimetriks and Profound loans.
Net gain on financial assets	• Net gain in Q3-17 driven by realized gain of $1,457 upon the disposal of common shares of Merus and a realized gain of $276 on distributions of a strategic fund, offset by fair value revaluation of derivatives.	• Net gain in YTD-17 due to realized gains on the sale of equities, gains on distributions of strategic funds and recognition of derivatives.
Net gain on financial assets measured at fair value through profit or loss	• As a result of the revaluation of strategic funds, loans and equities measured at FVPL. • Net gain mainly attributed to a mark to market adjustment of $6,795 [EUR 4,524] related to the investment in Forbion due to the IPO of Replimune, an investment held by Forbion, and the revaluation of TXMD shares. • Refer to Sections 8 and 9 for further details.	
Share of net income of associate	• No significant variance.	
Foreign exchange loss (gain)	• Loss in Q3-18 explained by relative losses on certain U.S. dollar denominated financial assets as Canadian dollar strengthened.	• Gain in YTD-18 due to relative gains on certain U.S. dollar denominated financial assets as Canadian dollar weakened.
Income tax expense	• Variance due to gains on investments in financial assets and amortization of deferred income taxes related to the Company's financing.	

[1] *Other income includes income earned for advisory and other services, gains from early loan repayments and income from strategic lending deals*

(In thousands of Canadian dollars, except for share and per share amounts)

FINANCIAL CONDITION

Section 4 – Balance Sheet

	September 30, 2018	December 31, 2017	**Change $**	**%[1]**
ASSETS				
Current				
Cash and cash equivalents	**303,222**	496,460	(193,238)	39%
Marketable securities	**416,762**	232,573	184,189	79%
Trade and other receivables	**8,824**	9,176	(352)	4%
Inventories	**1,233**	1,224	9	1%
Other current financial assets	**29,093**	58,848	(29,755)	51%
Income taxes receivable	**790**	792	(2)	0%
Total current assets	**759,924**	799,073	(39,149)	5%
Marketable securities	**55,062**	36,000	19,062	53%
Property and equipment	**680**	633	47	7%
Intangible assets	**17,161**	12,576	4,585	36%
Other financial assets	**102,481**	76,988	25,493	33%
Investment in associate	**79,031**	75,983	3,048	4%
Deferred income tax assets	**3,727**	4,730	(1,003)	21%
Other receivable	**23,340**	—	23,340	100%
Total assets	**1,041,406**	1,005,983	35,423	4%
LIABILITIES AND SHAREHOLDERS' EQUITY				
Current				
Accounts payable and accrued liabilities	**5,401**	5,025	376	7%
Income taxes payable	**10,702**	7,599	3,103	41%
Other balances payable	**1,393**	1,354	39	3%
Deferred other income	**247**	282	(35)	12%
Total current liabilities	**17,743**	14,260	3,483	24%
Deferred other income	**—**	167	(167)	N/A
Other balances payable	**3,261**	348	2,913	837%
Total liabilities	**21,004**	14,775	6,229	42%
Shareholders' equity				
Share capital	**761,788**	761,490	298	0%
Warrants	**785**	785	—	—
Contributed surplus	**13,863**	12,196	1,667	14%
Accumulated other comprehensive income	**12,065**	20,907	(8,842)	42%
Retained earnings	**231,901**	195,830	36,071	18%
Total shareholders' equity	**1,020,402**	991,208	29,194	3%
Total liabilities and shareholders' equity	**1,041,406**	1,005,983	35,423	4%

[1] *Percentage change is presented in absolute values*

(In thousands of Canadian dollars, except for share and per share amounts)

September 30, 2018 vs December 31, 2017

Cash and cash equivalents and marketable securities	• Refer to Section 6 – Liquidity and Capital Resources for further information.
Trade and other receivables	• No significant variance.
Inventories	• No significant variance.
Other financial assets (current and long term)	• Decrease of $4,262 driven by: **Loans and other receivables:** decrease of $34,185 mainly attributable to early repayments of $25,894 [US$20,000] of the Medimetriks loan, $5,613 [US$4,460] of the 60P loan and the Profound loan of $2,857. Refer to Section 7 for further information on Knight's strategic lending portfolio. **Equities, Warrants and Derivatives:** increase of $5,224 driven by investments in and the revaluation of equities, warrants and derivatives. Refer to note 8 in the Interim Financial Statements for further information. **Funds:** increase of $24,699 due to capital calls of $20,560, mark-to-market adjustments of $9,275 and foreign exchange gains of $1,291 offset by distributions of $6,427. Refer to Section 9 for further information on Knight's strategic investments.
Income tax receivable	• No significant variance.
Property and Equipment	• No significant variance.
Intangible assets	• Increase due to the in-licensing of products, offset by amortization. • Refer to note 7 in the Interim Financial Statements for further details.
Investment in associate	• Increase related to Knight's share of net income and other comprehensive income. • Refer to Section 10 for further information.
Other receivable	• Refer to Section 5 for further information.
Accounts payable and accrued liabilities	• Increase due to timing of purchases and payments.
Income tax payable	• Increase due to gains on investments in financial assets and foreign exchange.
Deferred other income	• No significant variance.
Other balances payable (current and long term)	• Increase due to regulatory and sales milestones recorded in 2018 that Knight expects to pay.
Share capital	• Refer to note 12 in the Interim Financial Statements for further information.
Contributed surplus	• Increase related to share-based compensation expense. • Refer to the statement of changes in shareholders' equity in the Interim Financial Statements for further information.
Accumulated other comprehensive income	• Decrease related to the IFRS 9 transition adjustment of $11,692, offset by other comprehensive income of $2,850 for the period. • Refer to the statement of changes in shareholders' equity and note 2 in the Interim Financial Statements for further information.
Retained earnings	• Increase due to net income of $23,858 in YTD-2018 and the IFRS 9 transition adjustment of $12,213. • Refer to note 2 in the Interim Financial Statements for further details.

(In thousands of Canadian dollars, except for share and per share amounts)

Section 5 – Notice of Reassessment from CRA

In July 2018, Knight received a notice of reassessment from the CRA for its fiscal year 2014 related to the disposition of a PRV held by Knight's wholly-owned subsidiary, Knight Therapeutics (Barbados) Inc. A PRV is a transferrable asset that entitles the holder to a priority review for a drug of its choice. A priority review means that the review time of the FDA for a new drug application is reduced by approximately six months. The PRV program was designed to incentivize the development of treatments for diseases that might otherwise not attract development interest due to the cost and the lack of market opportunities.

The Company's PRV was granted on March 19, 2014 upon the FDA approval of Impavido® and was disposed of to a third party in November 2014 for gross proceeds of US$125,000. The notice of reassessment provides that Knight is liable to pay to the CRA an aggregate of $23,340 in additional taxes and interest. Knight has made a deposit for the full amount to the CRA in July 2018.

Knight believes that the reassessment is unfounded and has filed a notice of objection in September 2018 to start the appeals process. Based on the Company's view of the likely outcome of the appeals process, Knight expects to recover the $23,340 remitted to the CRA and has not recorded any tax provision related to the disposal of the PRV in its financial statements. However, there can be no assurance regarding the outcome or when a resolution may be reached.

Furthermore, it is likely that the Quebec Revenue Agency will propose a similar adjustment which will result in an estimated additional tax liability of $19,000. Although Knight believes its tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from historical income tax provisions and accruals.

Section 6 – Liquidity and Capital Resources

The Company's Investment Policy governs the investment activities relating to cash resources. An Investment Committee composed of representatives from management and the Board of Directors monitors compliance with said policy. The Company invests in strategic investments in the form of equity funds, debt funds, equity or liquid investment securities with varying terms to maturity, selected with regard to the expected timing of investments and expenditures for continuing operations and prevailing interest rates.

The Company believes that its existing cash, cash equivalents and marketable securities as well as cash generated from operations are sufficient to finance its current operations, working capital requirements and future product and corporate acquisitions. The table below sets forth a summary of cash flow activity and should be read in conjunction with our consolidated statements of cash flows.

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2018	2017	**$**	**%**[1]	**2018**	2017	**$**	**%**[1]
Net cash from operating activities	**(19,916)**	10,736	(30,652)	N/A	**(8,992)**	18,343	(27,335)	N/A
Net cash from investing activities	**(93,420)**	(30,402)	(63,018)	207%	**(188,209)**	(24,178)	(164,031)	678%
Net cash from financing activities	**148**	61	87	143%	**239**	499	(260)	52%
Decrease in cash and cash equivalents during the period	**(113,188)**	(19,605)	(93,583)	477%	**(196,962)**	(5,336)	(191,626)	3591%
Net foreign exchange difference	**(1,948)**	(1,435)	(514)	36%	**3,724**	(2,767)	6,491	N/A
Cash and cash equivalents, beginning of the period	**418,358**	527,879	(109,520)	21%	**496,460**	514,942	(18,482)	4%
Cash and cash equivalents, end of the period	**303,222**	506,839	(203,617)	40%	**303,222**	506,839	(203,617)	40%
Marketable securities, end of the period	**471,824**	254,248	217,576	86%	**471,824**	254,248	217,576	86%
Cash, cash equivalents, and marketable securities, end of the period	**775,046**	761,087	13,959	2%	**775,046**	761,087	13,959	2%

[1] *Percentage change is presented in absolute values*

(In thousands of Canadian dollars, except for share and per share amounts)

Net cash from operating activities	Primarily relates to cash generated through revenues and interest received, offset by operating expenses including salaries, research and development expenses, advertising and promotion costs, and other corporate expenses. In addition, during Q3-18 Knight deposited $23,340 to the CRA related to the sale of the PRV in 2014. Cash flows from operating activities exclude revenues and expenses not affecting cash, such as unrealized and realized gains or losses on financial assets, accretion of interest, share based compensation expense, depreciation and amortization, foreign exchange gains or losses, share of net income and dividends from associate, other income, deferred other income, and net changes in non-cash balances relating to operations.	
Net cash from investing activities	For the three-month period ended September 30, 2018, cash flows were due to: • net purchases of marketable securities of $84,519; • net investments in life sciences funds of $6,030; • net purchases of equity investments of $6,185; • acquisition of property and equipment of $9, offset by • net proceeds from repayments of loan receivables of $3,323.	For the nine-month period ended September 30, 2018, cash flows were due to: • net purchases of marketable securities of $202,627; • net investments in life sciences funds of $14,133; • net purchases of equity investments of $5,880; • acquisition of intangibles and property and equipment of $3,095, offset by • net proceeds from repayments of loan receivables of $37,526.
Net cash from financing activities	Cash flows from financing activities were due to the participation of employees and directors in the Company's share purchase plan and cash received from the exercise of stock options.	

PRODUCT ACQUISITION STRATEGY

Section 7 – Products

Knight pursues opportunities to acquire or in-license pharmaceutical products, consumer health products and medical devices in Canada and select international markets. Knight's wholly owned subsidiary in Barbados develops innovative pharmaceuticals including those used to treat neglected tropical diseases and rare pediatric diseases. Knight expects to expand its product portfolio within existing therapeutic fields in Canada and internationally, and intends to leverage its expertise in specialty sales and marketing, product acquisition and in-licensing to gain a competitive advantage in delivering pharmaceutical products to the marketplace, thereby decreasing scientific risks, long development timelines and high development costs. The following table summarizes certain products from Knight's product portfolio.

Prescription Pharmaceutical Products

Product	Indication/Potential Indication	Licensor	Status in Territory	Territory Rights
Pain/Gastrointestinal				
Movantik®	OIC	AstraZeneca	Marketed in CAN and approved in ISR	CAN, ISR
Probuphine™	Opioid addiction	Braeburn	Marketed	CAN
Ibsrela™ (tenapanor)	IBS-C	Ardelyx	Pending submission	CAN
	Hyperphosphatemia		Phase 3	
Mytesi®	Symptomatic relief of non-infectious diarrhea in adult patients with HIV or AIDS on ART.	Jaguar	Pending submission	CAN, ISR
	Other diarrhea disorders		Pre-clinical – Phase 2	
NeurAxon family	Acute migraine, pain and neurological disorders	N/A	Pre-Clinical – Phase 3	CAN, ISR, RUS, ZAF
Antibe family	Chronic pain and inflammation	Antibe	Pre-clinical – Phase 2	CAN, ISR, RUS, ZAF

Prescription Pharmaceutical Products (continued)

Product	Indication/Potential Indication	Licensor	Status in Territory	Territory Rights
Ophthalmic				
AzaSite™	Bacterial conjunctivitis	Akorn	Approved	CAN
Iluvien®	Diabetic macular edema	Alimera	Submitted	CAN
Netildex™	Ocular inflammation	SIFI	Submitted	CAN
Women's Health				
TX-004HR	Moderate-to-severe dyspareunia	TXMD	Pending submission	CAN, ISR
TX-001HR	Moderate-to-severe vasomotor symptoms due to menopause	TXMD	Pending submission	CAN, ISR
Other				
Impavido®	Leishmaniasis	N/A	Marketed	Global
Arakoda™ 60P family	Prevention of malaria Other tropical diseases	60P	Pending submission Phase 2	CAN, ISR, RUS, LATAM[1]
Advaxis family	HPV-associated cancers and others	Advaxis	Phase 1 – Phase 3	CAN

[1] *Select products only for LATAM*

Consumer Health Products and Medical Devices

Product	Description	Licensor	Status in Territory	Territory Rights
Neuragen®	Pain associated with diabetic and peripheral neuropathy	N/A	Marketed[1]	Global (Ex. U.S)
Synergy Family	Various consumer health products	Synergy	Marketed[2]	CAN, ISR, ROM, RUS, ZAF
FLEXISEQ™	Pain and joint stiffness associated with osteoarthritis	PBB	Submitted	QUE, ISR
Crescita family	Dermo-cosmetic line of products	Crescita	Not Yet Marketed	ISR, ROM, RUS, ZAF, CAR
TULSA-PRO®	Prostate ablation	Profound	Pending submission	CAN

[1] *Approved and marketed in Canada and the UAE*
[2] *Select products marketed*

Highlights

Movantik®

In December 2016, Knight entered into an agreement with AstraZeneca for the rights to Movantik® in Canada and Israel under which Knight is responsible for all commercial, regulatory and certain supply chain activities. Movantik® is the first once-daily oral peripherally-acting mu-opioid receptor antagonist for the treatment of OIC in adult patients with non-cancer pain who have had an inadequate response to laxatives. According to the Canadian Family Physician Practice Guideline, it is estimated

that at least 26% of chronic opioid users suffer from OIC. According to IQVIA data, Movantik® sales in Canada were $343 and $963 for the three and nine-month periods ended September 30, 2018 (2017: $255 and $634).

Probuphine™

On February 1, 2016, Knight entered into an exclusive licensing agreement with Braeburn to commercialize Probuphine™ in Canada. Probuphine™, indicated for the treatment of opioid drug dependence, is a subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention. Health Canada approved Probuphine™ on April 18, 2018 for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counselling and psychosocial support. On October 29, 2018, Knight announced the commercial launch of Probuphine™ in Canada.

Ibsrela™

On March 16, 2018, Knight entered into an exclusive licensing agreement to commercialize Ibsrela™ in Canada. Ibsrela™ is a first-in-class small molecule treatment that has completed Phase 3 development for IBS-C and is being evaluated in a second Phase 3 study for hyperphosphatemia. Knight expects to submit a NDS for Ibsrela™ for IBS-C in 2019.

Iluvien®

On July 21, 2015, Knight entered into an agreement with Alimera pursuant to which Knight acquired the exclusive Canadian distribution rights to Iluvien®, a sustained release intravitreal implant for the treatment of diabetic macular edema. On February 22, 2017, Iluvien® was accepted for review by Health Canada. On March 13, 2018, Knight was advised by Health Canada that the NDS for Iluvien® will not be approved at this time. Knight received a Notice of Non-Compliance and responded to Health Canada's issues within the prescribed 90-day window.

Netildex™

On August 2, 2016, Knight entered into a license agreement for the exclusive rights in Canada to commercialize Netildex™, a fixed combination of netilmicin and dexamethasone for the treatment of inflammatory ocular conditions of the anterior segment of the eye, in presence or at risk of bacterial infection. On February 15, 2018, Netildex™ was accepted for review by Health Canada.

TXMD

On July 31, 2018, Knight entered into an exclusive licensing agreement for the commercial rights of TX-004HR and TX-001HR in Canada and Israel. TX-004HR is a TXMD FDA-approved product, marketed as Imvexxy™ (estradiol vaginal inserts) in the U.S., for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. TX-001HR, approved by the U.S. FDA in October 18, 2018, is a bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause. Knight expects to submit a NDS in Canada for TX-004HR and TX-001HR in 2019.

Jaguar

On September 24, 2018, Knight entered into a distribution, license and supply agreement with Jaguar that grants Knight the exclusive right to commercialize Mytesi® (crofelemer 125 mg delayed-release tablets) and related products in Canada and Israel and a right of first negotiation to commercialize Mytesi and related products in specified Latin American countries. Mytesi is an FDA-approved product in the U.S. indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV or AIDS on ART.

(In thousands of Canadian dollars, except for share and per share amounts)

Arakoda™

On December 10, 2015, the Company entered into a loan agreement with 60P for the development of tafenoquine for the prevention of malaria in adults. As consideration for the loan, Knight received the commercial rights of the Product for Canada, Israel and Russia. The Product was approved by the FDA on August 9, 2018.

Impavido®

On February 27, 2018, Knight acquired the worldwide rights to Impavido® as part of its business separation agreement with Paladin. Impavido® is an oral drug treatment based on miltefosine for the visceral, cutaneous and mucocutaneous leishmaniasis which is caused by a protozoa parasite from over 20 Leishmania species and is approved for sale in the U.S, Germany and Israel. Impavido® was launched in the U.S in March 2016 by Knight's commercialization partner, Profounda. On August 1, 2018, Knight out-licensed the commercial rights of Impavido® for the territories of Colombia, Peru, Ecuador and Paraguay to Pharma Consulting Group S.A.

Section 8 – Strategic Lending

Knight finances other life sciences companies in all geographic markets with the goal of strengthening relationships in the life sciences industry and securing product distribution rights for Canada and select international markets. Typically, loans have low double-digit interest rates and may come with additional consideration to the Company. Loans often come with product rights or product options for Canada and select international markets. These loans strengthen Knight's ties within the life sciences industry and, in doing so, help to secure product rights for Knight either on a direct or indirect basis. As of the date hereof, Knight has seven secured loans outstanding to life sciences companies as outlined in the table below. To date, the strategic lending portfolio has led to the acquisition or in-licensing of Knight's consumer health products (as described in Section 7), the Antibe family, the 60P family and TULSA-PRO®.

	Nominal loan balance as at September 30, 2018	
Entity	**In Source Currency**	**In Canadian Dollars[1]**
Synergy	US$8,000	$10,356
60P[3]	US$5,719	$7,403
Crescita	C$3,639	$3,639
Medimetriks	US$1,250	$1,618
Pediapharm[2]	C$1,250	$1,250
Ember	US$500	$647
Total		**$24,913**

[1] Converted at the Bank of Canada closing exchange rates on September 30, 2018
[2] Pediapharm debenture is held indirectly through the Bloom Burton Healthcare Lending Trust
[3] Excludes 60P Convertible Debenture received as consideration for loans issued to 60P

(In thousands of Canadian dollars, except for share and per share amounts)

The following table summarizes the movement in loans and other receivables during the nine-month period ended September 30, 2018.

	Carrying value beginning of period $	Additions $	Loan repayments $	Net gain on FA[1] $	Foreign exchange[2] $	Carrying value end of period $	Current other financial assets $	Non-current other financial assets $
Amortized Cost	3,370	1,151	(611)	—	71	3,981	—	3,981
FVTPL	56,970	1,341	(38,867)	791	1,418	21,653	4,546	17,107
Total	**60,340**	**2,492**	**(39,478)**	**791**	**1,489**	**25,634**	**4,546**	**21,088**

[1] Net changes related to change in the fair value of loan receivables and recognition of day 1 gains
[2] Net changes due to foreign currency translation recorded in the statement of income or statement of other comprehensive income

During the nine-month period ended September 30, 2018, as a result of changes in fair value and recognition of deferred day 1 gains, the Company recorded a gain of $791 in the statement of income as net gain on financial assets measured at fair value through profit and loss. In addition, the Company recorded $1,489 due to foreign currency revaluation of which $870 is recorded in the statement of income as foreign exchange gain and $619 recorded in the statement of other comprehensive income as unrealized gain on translation of foreign operations.

During the three-month period ended September 30, 2018, as a result of changes in fair value and recognition of deferred day 1 gains, the Company recorded a loss of $394 in the statement of income as net gain on financial assets measured at fair value through profit and loss. In addition, the Company recorded a loss of $373 due to foreign currency revaluation of which $47 is recorded in the statement of income as foreign exchange loss and $326 recorded in the statement of other comprehensive income as unrealized loss on translation of foreign operations.

Highlights

Loans and other receivables measured at amortized cost

Antibe

On November 13, 2015, Knight invested $500 in senior secured convertible debentures offered by Antibe. As consideration for the debenture, the Company received a conversion feature whereby up to the maturity date, the debenture can be converted into common shares of Antibe at $0.22 per share ("Antibe Conversion Option"). On March 27, 2018, Knight exercised its Antibe Conversion Option and was issued 2,489,889 common shares. As a result, Knight derecognized the loan and derivative and recognized an equity investment measured at FVPL of $996.

Loans and other receivables measured at FVTPL

Medimetriks

During 2016, Knight issued $31,290 [US$23,000] to Medimetriks in secured loans to support its acquisition of the exclusive U.S. development and commercialization rights of OPA-15406 from Otsuka. On March 7, 2018, Knight received an early repayment of principal of $25,894 [US$20,000] and interest and fees of $3,569 [US$2,757].

60P

On December 10, 2015, the Company entered into a loan agreement with 60P ("60P Loan") for the development of tafenoquine ("Product") for the prevention of malaria in adults. As at December 31, 2017, the nominal loan balance was $11,472 [US$9,145]. On February 8, 2018, 60P repaid $5,613 [US$4,460] reducing the nominal loan balance to $5,859 [US$4,685].

(In thousands of Canadian dollars, except for share and per share amounts)

On April 24, 2018, Knight amended its loan agreement with 60P and committed to lend up to an additional $2,694 [US$2,100] at an interest rate of 15%, to support the regulatory approval and commercialization of tafenoquine ("60P Amendment"). As consideration for the 60P Amendment, 60P committed to pay Knight an additional $3,848 [US$3,000] plus annual interest of 9% on April 23, 2023 ("60P Debenture"). Under the terms of the 60P Convertible Debenture, Knight has the right to convert the 60P Convertible Debenture into common shares of 60P at a pre-determined exercise price at any time prior to the maturity date ("60P Conversion Feature"). Furthermore, 60P and Knight entered into an exclusive license agreement granting Knight the right to commercialize tafenoquine in Latin America.

As a result of the 60P Amendment, the Company recorded the Additional 60P Loan and a hybrid financial instrument representing the 60P Debenture and the 60P Conversion Feature ("60P Hybrid Instrument") at their respective relative fair values of $452 [US$352] and $380 [US$296]. At the date of the transaction, the fair value of the 60P Loan was $6,304 [US$4,914] determined using the discounted cash flow approach with a discount rate of 20.01%. The fair value of the 60P Hybrid Instrument was $1,958 [US$1,526] determined by the sum of the fair values of the 60P Debenture and 60P Conversion Feature derived respectively using the discounted cash flow approach and the Black-Scholes model.

The Product was approved by the FDA on August 9, 2018. As at September 30, 2018, Knight has a nominal loan balance of $7,403 [US$5,719] outstanding from 60P.

Profound

On April 30, 2015, the Company entered into a secured debt agreement with Profound, whereby it issued $4,000 bearing interest at 15% per annum and maturing on June 3, 2019. On July 26, 2018, Knight received an early repayment of $3,188 from Profound, including full repayment of the outstanding principal, interest and fees.

Section 9 – Strategic Investments

Fund Investments

Knight invests in life sciences venture capital funds in which the Company earns a return similar to any other limited partner in the fund and receives preferential access to innovative healthcare products from around the world for Canada and select international markets. Since inception of the fund strategy, Knight has committed to invest with the following capital fund managers for approximately $126,653. To date, the investments in venture capital funds have led to the Canadian in-license of Iluvien® from Alimera and a portfolio of products from Advaxis.

The fair value of the funds held by Knight, as at September 30, 2018, is $79,667.

	Fund Commitments	
Entity	**In Source Currency**	**In Canadian Dollars[1]**
Teralys Capital	C$30,000	$30,000
Domain Associates LLC	US$25,000	$29,063
Forbion Capital Partners	EUR 19,500	$27,550
Sectoral Asset Management[2]	US$13,000	$13,919
Sanderling Ventures LLC	US$10,000	$11,625
HarbourVest Partners LLC	C$10,000	$10,000
TVM Capital GmbH	US$1,600	$1,996
Bloom Burton Healthcare Lending Trust[3]	C$1,500	$1,500
Genesys Capital Management (Fund III) Inc.	C$1,000	$1,000
Total		**$126,653**

[1] Converted at the Bank of Canada noon exchange rates as of the commitment date (using the September 30, 2018 closing rates total fund commitment would be $135,996)

[2] Knight received a full return of capital from its US$13,000 investment in Sectoral's NEMO II and subsequently committed to reinvest US$10,000 into Sectoral's NEMO III

[3] Represents an investment in a debt fund

(In thousands of Canadian dollars, except for share and per share amounts)

Fund investments

The following table summarizes the movement in fund investments during the nine-month period ended September 30, 2018.

	Carrying value beginning of period	Additions[1]	Distributions[2]	Net gain on FA	Foreign exchange[3]	Carrying value end of period	Current other financial assets	Non-current other financial assets
	$	$	$	$	$	$	$	$
2018	**54,968**	**20,560**	**(6,427)**	**9,275**	**1,291**	**79,667**	**—**	**79,667**

[1] Investments in equity or debt funds
[2] Distributions received from funds in the nine-month period ended September 30, 2018 generated realized gain of $1,790 (three-month period ended September 30, 2018: realized loss of $21) (recorded in the current and historical consolidated statements of income through revaluation of the fund investments)
[3] Net changes due to foreign currency translation, recorded in the statement of income or statement of other comprehensive income

2018

During the nine-month period ended September 30, 2018, Knight invested $20,560 [including US$6,668 and EUR 2,686] and received distributions of $6,427 [including US$1,275 and EUR 2,586]. The Company recorded a net increase of $9,275 in the statement of income due to mark to market adjustments. Furthermore, the Company recorded a net increase of $1,291 due to foreign currency revaluation, of which $348 is recorded in the statement of income as foreign exchange gain, and $943 is recorded in the statement of other comprehensive income as unrealized gain on translation of foreign operations.

During the three-month period ended September 30, 2018, Knight invested $6,358 [including US$3,227 and EUR 821] and received distributions of $328. The Company recorded a net increase of $7,716 in the statement of income due to mark to market adjustments. Furthermore, the Company recorded a net decrease of $965 due to foreign currency revaluation, of which $123 is recorded in the statement of income as foreign exchange loss, and $842 is recorded in the statement of other comprehensive income as unrealized gain on translation of foreign operations.

Forbion

In March 2018, it was announced that Lundbeck acquired Prexton, an investment held by Forbion. The transaction closed for an upfront cash payment of $158,670 [EUR 100,000] and up to $1,277,294 [EUR 805,000] in contingent payments. On March 29, 2018, Knight received a distribution of $3,168 [EUR 1,609] from Forbion upon close of the acquisition of Prexton.

In July 2018, Replimune, an investment held by Forbion, completed an IPO on NASDAQ, raising over US$100 million at a valuation of US$15 per common share. As a result, Knight recorded a mark to market adjustment of $6,795 [EUR 4,524] as net gain on financial assets measured at fair value through profit or loss in the statement of income.

Other investments

Increased ownership in Crescita

Knight received 2,079,973 rights (the "Rights") issued under the terms of Crescita's Rights Offering Circular dated February 2, 2018 (the "Rights Offering"). Each two Rights entitled Knight to subscribe for one common share of Crescita at $0.53 per share. On March 9, 2018, the Company exercised its Rights and invested $400 and received 754,716 common shares of Crescita under the Rights Offering.

Antibe

On March 27, 2018, Knight exercised its Antibe Conversion Option and converted its $500 debenture into 2,489,889 common shares, which were all sold during the quarter ended June 30, 2018 for $1,011.

(In thousands of Canadian dollars, except for share and per share amounts)

TXMD

On July 31, 2018, Knight entered into an exclusive licensing agreement for the commercial rights of TX-004HR and TX-001HR in Canada and Israel. In conjunction with the agreement, Knight invested $26,028 [USD$20,000] in the public offering of common shares of TXMD at a price of $6.64 [US$5.10] per share. As at September 30, 2018, the Company owns 1,308,992 shares of TXMD.

For additional details regarding the movement in equities or derivatives held by Knight throughout the quarter, refer to note 8 "Other Financial Assets" of the Interim Financial Statements.

Section 10 – Rest of World Strategy

Knight's international strategy is focused on identifying potential products and companies that fit within its existing business model, but that are located in select areas such as Israel, Australia, Latin America, Romania, Russia, Sub-Saharan Africa, the Caribbean and other countries excluding the U.S., Western Europe, Japan and China. Knight intends to continue its growth by becoming an international specialty pharmaceutical company and believes that these countries provide potentially significant growth and value opportunities.

Investment in Medison

On September 9, 2015, Knight acquired a 28.3% ownership interest in Medison, a privately-owned specialty pharmaceutical company based in Israel. The consideration given for the equity interest in Medison amounted to $82,001, which includes the fair value of 10,330,884 common shares of Knight issued to Medison and its controlling shareholder and a contingent consideration of $1,100. In addition, the Company incurred $217 of transaction costs which were capitalized with the investment. On June 16, 2016, the Company issued 250,000 common shares at a price of $8.29 per share for $2,073 and reduced the amount of contingent consideration recorded in contributed surplus upon the initial investment in Medison by $943. Consequently, the Company recorded an increase of $1,130 in the investment in associate. There is no further contingent consideration payable to Medison.

The interest in Medison is accounted for using the equity method of accounting. The investment was originally recorded at cost and subsequently adjusted to include the Company's share of Medison's net income and any dividends issued to the Company. The net income is adjusted to reflect the amortization of the fair value adjustments related to the Company's share of the net identifiable assets of Medison acquired and their tax impact.

This selected information is derived from our financial statements.

	Q3-18	**Q2-18**	Q1-18	Q4-17	Q3-17	Q2-17	Q1-17	Q4-16
Carrying value of investment	**79,031**	**78,990**	77,697	75,983	75,642	78,003	77,907	80,113
Amortization of FMV adjustments	**(1,378)**	**(1,378)**	(1,378)	(1,529)	(1,572)	(1,503)	(1,503)	(1,749)
Share of net income (loss), net of FMV adjustment	**89**	**(151)**	503	341	98	96	319	38
Dividends	**—**	**—**	—	—	2,459	—	2,525	—

The Company is presenting select financial information derived from Medison's consolidated financial statements, excluding amortization of fair value adjustments on acquisition in ILS using Israeli GAAP converted into IFRS in CAD for information purposes:

	Q3-18	**Q2-18**	**Q1-18**	Q4-17	Q3-17	Q2-17	Q1-17	Q4-16
Revenues	**63,482**	**64,260**	**60,259**	57,399	56,030	51,749	51,264	52,115
Net income	**5,189**	**4,352**	**6,653**	6,614	5,906	5,655	6,445	6,321

RISK MANAGEMENT

Section 11

10.1 Currency Risk

Knight holds a significant portion of its net financial assets in US$, EUR and ILS which results in financial risk due to fluctuations in the value of the currencies relative to the Canadian dollar. Assuming that all other variables remain constant, a 5% change in the Canadian dollar against the US$, EUR and ILS would have resulted in a change in the statement of income and comprehensive income of $11,582, $1,156 and $130, respectively.

10.2 Equity Price Risk

Equity price risk arises from changes in market prices of the equity and fund investments and derivatives. The carrying values of investments subject to equity price risk are $104,899 as at September 30, 2018 (December 31, 2017: $75,130). The Company monitors its equity investments for impairment on a periodic basis and at least every reporting period. Market prices are subject to fluctuation and, consequently, the amount realized in the subsequent sale of an investment may significantly differ from the reported market value. Fluctuation in the market price of a security may result from perceived changes in the underlying economic characteristics of the investee, the relative price of alternative investments and general market conditions. Furthermore, amounts realized in the sale of a particular security may be affected by the relative quantity of the security being sold. The Company's Board of Directors regularly reviews and approves equity investment decisions.

10.3 Interest Rate Risk

The Company is subject to interest rate risk on its cash, cash equivalents and marketable securities. Details regarding maturity dates and effective interest rates are described in notes 4 and 5 of the Interim Financial Statements. The Company does not believe that the results of operations or cash flows would be materially affected to any significant degree by a sudden change in market interest rates relative to interest rates on the investments, owing to the relatively short-term nature of the marketable securities and currently low market yields.

10.4 Liquidity Risk

The majority of the Company's financial liabilities are short term in nature. The Company generates sufficient cash from operating activities to fund its operations and fulfil its obligations as they become due. The Company has sufficient funds available through its cash, cash equivalents and marketable securities, should its cash requirements exceed cash generated from operations to cover all financial liability obligations. As at September 30, 2018, there were no restrictions on the flow of these funds nor have any of these funds been committed in any way, except as set out in note 19 of the Interim Financial Statements.

10.5 Credit Risk

The Company considers its maximum credit risk to be $113,709 (December 31, 2017: $122,490) which is the total of the following assets: trade and accounts receivable, interest receivable, loans receivable and investment in funds. The marketable securities and cash equivalent balances are subject to minimal risk of changes in value. They are invested within four large Canadian financial institutions, five Canadian credit unions guaranteed by provincial governments, three foreign affiliates of large Canadian financial institutions, and one Canadian insurance company, comprised of thirty-two guaranteed investment certificates, one guaranteed investment fund, eight term deposits and six bearer deposit notes.

The Company is exposed to credit risk from its customers and continually monitors its customers' credit. It establishes the provision for doubtful accounts based upon the credit risk applicable to each customer. The credit risk on loans and interest receivable is due to the risk of insolvency or operational failure of the partners in the strategic lending transaction. The

(In thousands of Canadian dollars, except for share and per share amounts)

Company also has a credit risk on its investment in funds and derivatives which are held through venture funds or issued by a counterparty.

10.6 Risk Factors

For a detailed discussion of additional risk factors, please refer to the Company's Annual Information Form for the year ended December 31, 2017 on SEDAR at www.sedar.com.

ADDITIONAL INFORMATION

Section 12 – Selected Quarterly Financial Information

This selected information is derived from our Interim Financial Statements.

	Q3-18	Q2-18	Q1-18	Q4-17	Q3-17	Q2-17	Q1-17	Q4-16
Revenues	**3,220**	2,238	3,154	2,544	1,860	2,480	1,750	1,845
Net income	**12,930**	4,019	6,909	7,145	3,593	459	6,047	7,939
EPS								
Basic	**0.091**	0.028	0.048	0.050	0.025	0.003	0.042	0.059
Diluted	**0.090**	0.028	0.048	0.050	0.025	0.003	0.042	0.059
Cash, cash equivalents and marketable securities	**775,046**	806,746	802,425	765,033	761,087	761,161	763,778	736,050
Total assets	**1,041,506**	1,029,133	1,016,853	1,005,983	993,467	991,980	994,293	990,770
Total non-current liabilities	**3,261**	1,127	1,171	515	1,028	1,200	1,263	1,294

The Company has not paid dividends on its common shares and does not anticipate declaring any dividends in the near future.

Section 13 – Outstanding Share Data

The table below summarizes the share data:

As at	**November 7, 2018**
Common Shares	142,843,871
Stock Options	4,102,469
Warrants	406,126

Section 14 – Use of Proceeds from Financing

To date, Knight has raised net proceeds of approximately $685,000 from five public offerings. In our short form prospectuses related to the offerings, Knight disclosed that its intent was to use a substantial portion of the net proceeds (i) for potential acquisitions of (a) in-licensing of over-the-counter and prescription pharmaceutical products and targeted promotion of these products, and (b) specialty pharmaceutical businesses in select international markets, (ii) for financing of other life sciences companies in Canada and internationally as well as for investments in funds focused in the life sciences sector, and (iii) the remainder for general corporate purposes.

As at September 30, 2018, Knight had deployed or invested or committed to deploy or invest over $300,000 for the purposes disclosed in the prospectuses, as described above. Pending the application of the remainder of the net proceeds, Knight has invested part of the net proceeds in short-term investment-grade securities and bank deposits, and holds the remainder in

cash. Knight anticipates that it has sufficient funds available to achieve its business objectives and milestones as listed in the prospectuses.

Section 15 – Payment of Dividends

The Company has not paid dividends on its common shares since inception and does not anticipate declaring dividends in the foreseeable future. Knight's current policy is to retain earnings to finance the acquisition and development of new products and to reinvest in the growth of the Company. Any future determination to pay dividends is at the discretion of the Company's Board of Directors and will depend on the Company's financial condition, results of operations, capital requirements and other such factors as the Board of Directors of the Company deems relevant.

Section 16 – Product Pricing Regulation on Certain Patented Drug Products

All patented drug products that form part of Knight's portfolio of products are subject to pricing regulation by the PMPRB, a federal agency tasked with ensuring that prices of patented medicines are not excessive. For new patented products, the maximum non-excessive price in Canada is limited to a range with a lower bound set by the prices of existing comparable drugs sold in Canada and an upper bound set by the median prices for the same drug sold in a specified set of developed comparator countries. For existing patented products, prices cannot be increased annually by more than a factor based on Statistics Canada's Consumer Price Index. The PMPRB monitors compliance through a review of the average transaction price of each patented drug product as reported by pharmaceutical companies like Knight on a semi-annual basis. The PMPRB may from time to time deem certain of Knight's existing or future patented products to be excessively priced based on the application of its empowering legislation and regulations, including those related to price increases, the comparative assessment of new products and reductions in the highest price in international reference countries. Such determinations by the PMPRB may have a material adverse effect on Knight's financial condition and results of operations or cash flows.

The Canadian federal government has made a commitment to reduce the cost of prescription drug pending in Canada. On December 2, 2017, Health Canada published the following proposed key changes:

- changes in the comparator countries used to determine price ceilings. The changes include removal of the US (which generally has the highest international drug prices) and Switzerland and addition of seven new countries judged to have similar consumer protection-oriented mandates and relative wealth as Canada;
- new, economics-based price regulatory factors to allow the PMPRB to regulate based on the value of a medicine and its impact on the health care system; and,
- changes to certain reporting requirements, including reporting all discounts and rebates provided to third-party payers, such as provincial drug plans.

On June 25, 2018, the PMPRB presented a draft guidelines implementation framework which is intended to give effect of the proposed changes. The proposed amendments, if enacted, are expected to result in a decrease in the prices of patented drugs in Canada. The proposed regulations initially expected to come into force on January 1, 2019 will be delayed and the precise nature and timing of these changes (including the potential retroactive application of some) will not be known until the full consultation and Canada Gazette publication processes are completed.

The final form of regulatory changes to the PMPRB may have a significant adverse effect on the price of patented drugs sold by the Corporation in Canada and may limit the Corporation's ability to in-license and launch products in Canada due to more restrictive pricing regulations.

(In thousands of Canadian dollars, except for share and per share amounts)

Section 17 – Financial Instruments

The Company's investment policy regulates the investment activities relating to cash resources. The Company invests in strategic investments in the form of equity funds, debt funds, equity or liquid investment securities with varying terms to maturity, selected with regard to the expected timing of investments and expenditures for continuing operations, and prevailing interest rates.

Knight has not entered into any currency or other hedging instrument contracts during the period ended September 30, 2018. Refer to notes 8 and 9 of the Interim Financial Statements for the quarter ended September 30, 2018 for additional information.

Section 18 – Off-balance Sheet Arrangements

The Company's off-balance sheet arrangements consist of contractual obligations and agreements for development, sales, marketing and distribution rights to innovative drug products. The effect of terminating these arrangements under normal operating circumstances consists of an effective transition of the remaining responsibilities and obligations to the licensor under agreed upon time frames and conditions. Please refer to note 19 of the Interim Financial Statements for the period ended September 30, 2018 for additional information. Other than these contractual obligations and commitments, the Company does not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's financial condition, changes in revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

Section 19 – Commitments

In the normal course of business, the Company secures development, sales, marketing and distribution rights to innovative drug products requiring royalties or product payments considered normal operating commitments and as such not included herein. The Company has entered into various agreements which include contractual obligations extending beyond the current year. These obligations are classified into four major categories: operating lease, fund commitments, milestones and purchase commitments, and equity and loan commitments.

[i] Operating Lease

The Company is committed under operating leases for the lease of its premises. Future minimum annual payments are as follows:

	$
2018	75
2019	300
2020	300
2021	292
2022	230
Total	**1,197**

As at November 7, 2018, the operating lease commitment has decreased by $50.

[ii] Fund commitments

As at September 30, 2018, under the terms of Company's agreements with life sciences venture capital funds, $65,984 (2017: $89,325), including $19,015 [US$14,690] and $14,524 [EUR 9,669], may be called over the life of the funds (based on the closing foreign exchange rates).

As at November 7, 2018, $59,425 remains to be called by life science venture capital funds.

[iii] Milestones and purchase commitments

Under certain agreements, Knight may have to pay additional consideration should the Company achieve certain sales volumes or if certain milestones are met, such as regulatory approval in Canada. The Company may have to pay up to $99,114 including $29,651 [US$22,905] and $526 [EUR 350] upon achieving certain sales volumes, regulatory or other milestones related to specific products.

In addition, Knight has a commitment to purchase up to $2,041 [EUR 738 and US$721], of inventory for pharmaceutical products during the five-year period after their respective commercial launch. Furthermore, Knight has committed to certain sales force and marketing spend obligations during the five-year period after the commercial launch of one of its products.

[iv] Equity and loan commitments

Subject to loan agreements with its borrowers, Knight has committed to the following:

a) up to a maximum equity investment of $3,236 [US$2,500] to participate in the initial public offering of the borrower
b) up to an additional $1,412 [US$1,091] of a secured loan should the borrower meet certain conditions.

Section 20 – Related Party Transactions

Pharmascience Inc., a company related to the Company's CEO, provided administrative services of approximately $8 to the Company for the nine-month period ended September 30, 2018.

Section 21 – Segment Reporting

The Company has one reportable segment, and our principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets.

Section 22 – Significant Accounting Estimates and Assumptions

The preparation of the Company's consolidated financial statements requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts or revenues and expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Our significant accounting estimates and assumptions are reported in note 3 of our 2017 Annual Financial Statements and note 2.2 of our Interim Financial Statements.

Section 23 –Accounting Pronouncements Adopted in 2018

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's annual consolidated financial statements for the year ended December 31, 2017 except for IFRS 9 and IFRS 15 adopted on January 1, 2018. Refer to note 2.2 of the Interim Financial Statements for further details on the new accounting standards adopted. The Company has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

(In thousands of Canadian dollars, except for share and per share amounts)

Impact of transition to IFRS 9

Upon adoption of IFRS 9, the Company has not restated prior periods and the impact of the transition is as follows:

	As at December 31, 2017			As at January 1, 2018			
	IAS 39 Classification	IAS 39 Measurement	IAS 39 Carrying amount	IFRS 9 Classification & Measurement	IFRS 9 Carrying amount	Impact on Opening RE	Impact on AOCI
Cash	FVPL	FVPL	490,951	Amortized Cost	490,951	—	—
Cash Equivalents	FVPL	FVPL	5,509	Amortized Cost	5,509	—	—
Marketable securities	FVPL	FVPL	268,573	Amortized Cost	268,573	—	—
Loans and other receivables	Loans and receivables	Amortized Cost	59,819	Amortized Cost[1]	3,370	—	—
		FVPL	n/a	FVPL[2]	56,970	521	—
Equity investments	AFS	FVOCI	19,425	FVOCI	13,050	1,403	(1,403)
		FVPL	n/a	FVPL	6,375	670	(670)
Derivatives	FVPL	FVPL	1,624	FVPL	1,624	—	—
Fund investments	AFS	FVOCI	54,968	FVPL	54,968	9,619	(9,619)
Transition impact						**12,213**	**(11,692)**

[1] Strategic loans to Antibe and Pediapharm and other long-term receivables classified as amortized cost
[2] On transition, a Deferred day 1 gain of $1,125 remains to be recognized over term of loans. Refer to note 9 for additional details.

The impact on opening retained earnings and accumulated other comprehensive income is summarized below:

	RE	AOCI
Closing balance under IAS 39 (December 31, 2017)	195,830	20,907
Transition impact	12,213	(11,692)
Opening balance under IFRS 9 (January 1, 2018)	**208,043**	**9,215**

Impact of transition to IFRS 15

The transition to the new standard resulted in no adjustment to opening retained earnings as at January 1, 2018.

Section 24 – Recent Accounting Pronouncements

IFRS 16 – Leases

In January 2016, the IASB issued IFRS 16 Leases ("IFRS 16") which is effective on January 1, 2019 and replaces IAS 17 Leases ("IAS 17") and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is less than 12 months or the underlying asset has a low value. IFRS 16 substantially carries forward the lessor accounting in IAS 17 with the distinction between operating leases and finance leases being retained.

The Company will adopt IFRS 16 using the modified retrospective approach and expects to recognize $1,114 of right-of-use assets and $1,132 of lease liabilities with no material net impact on opening retained earnings.

Section 25 – Disclosure Controls and Procedures

The Company is committed to providing timely, accurate and balanced disclosure of all material information about the Company and to providing fair and equal access to such information. Management is responsible for establishing and maintaining its DC&P to ensure that information used internally and disclosed externally is complete and reliable. Due to the inherent limitations in all control systems, an evaluation of controls can provide only reasonable, not absolute assurance, that

all control issues and instances of fraud or error, if any, within the Company have been detected. Management continues to evolve and enhance its system of controls and procedures.

Section 26 – Internal Control Over Financial Reporting

The Company's management is responsible for establishing and maintaining adequate ICFR. The Company has designed ICFR to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with IFRS.

All control systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention or overriding of the controls or procedures. As a result, there is no certainty that our DC&P or ICFR will prevent all errors or all fraud.

During 2018, there was no significant changes in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect the Company's internal controls over financial reporting.

Section 27 – Subsequent Events

[i] Jaguar Health Inc.

On September 24, 2018, Knight entered into a distribution, license and supply agreement for the exclusive right to commercialize Mytesi® (crofelemer 125 mg delayed-release tablets) and related products in Canada and Israel and a right of first negotiation for specified Latin American countries. Mytesi® is an FDA-approved product in the U.S. indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV or AIDS on ART. Upon achievement of certain regulatory and sales milestones, Knight may have to pay up to $23,287 including $4,537 [US$3,505].

On October 2, 2018, Jaguar announced an underwritten public offering of its common stock, at US$0.60 per share, for gross proceeds of approximately US$9,000. On October 4, 2018, Knight invested $1,161 [USD$900] in common shares of Jaguar at a price of $0.77 [US$0.60] per share.

[ii] Commercial launch of Probuphine™

On October 29, 2018, Knight announced the commercial launch of Probuphine™ in Canada, for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counselling and psychosocial support.